Aequus Pharmaceuticals Inc.
AQSZF
$0.00
$0.00-53.85%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.76% | 185.18% | 240.14% | 124.62% | -30.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.76% | 185.18% | 240.14% | 124.62% | -30.11% |
| Cost of Revenue | 100.99% | 162.01% | 249.85% | 122.33% | 24.91% |
| Gross Profit | 130.68% | 205.88% | 233.80% | 126.41% | -49.52% |
| SG&A Expenses | -60.59% | -47.36% | -27.41% | -8.86% | -4.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.90% | -39.63% | -21.41% | -13.06% | -9.31% |
| Operating Income | 77.54% | 62.60% | 42.15% | 25.50% | 4.59% |
| Income Before Tax | 76.89% | 44.50% | 27.28% | 27.34% | 18.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 76.89% | 44.50% | 27.28% | 27.34% | 18.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.89% | 44.50% | 27.28% | 27.34% | 18.81% |
| EBIT | 77.54% | 62.60% | 42.15% | 25.50% | 4.59% |
| EBITDA | 88.03% | 69.01% | 45.22% | 25.54% | 4.54% |
| EPS Basic | 76.51% | 44.38% | 26.71% | 26.67% | 18.13% |
| Normalized Basic EPS | 67.74% | 54.00% | 36.63% | 21.15% | 18.42% |
| EPS Diluted | 76.51% | 44.38% | 26.71% | 26.67% | 18.13% |
| Normalized Diluted EPS | 67.74% | 54.00% | 36.63% | 21.15% | 18.42% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |